Bio-Techne (TECH) & Its Rivals Financial Review

Bio-Techne (NASDAQ:TECH) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its competitors? We will compare Bio-Techne to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Dividends

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.2% and pay out 44.8% of their earnings in the form of a dividend.

Volatility and Risk

Bio-Techne has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Bio-Techne’s competitors have a beta of 0.94, meaning that their average share price is 6% less volatile than the S&P 500.

Profitability

This table compares Bio-Techne and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Bio-Techne Competitors	-540.59%	-166.46%	-13.58%

Earnings and Valuation

This table compares Bio-Techne and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bio-Techne	$1.22 billion	$181.86 million	63.18
Bio-Techne Competitors	$2.26 billion	$55.88 billion	-13.89

Bio-Techne’s competitors have higher revenue and earnings than Bio-Techne. Bio-Techne is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Bio-Techne and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1	14	1	1	2.12
Bio-Techne Competitors	947	3161	5474	177	2.50

Bio-Techne currently has a consensus price target of $68.92, suggesting a potential downside of 5.14%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.75%. Given Bio-Techne’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Bio-Techne has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Bio-Techne beats its competitors on 8 of the 15 factors compared.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.